HCG Q4 FY26 Results Due May 20, 2026: Key Metrics Preview

Results schedule and what the board will consider

HealthCare Global Enterprises Ltd (HCG) is set to discuss its audited standalone and consolidated financial results for Q4 and FY26 ended March 31, 2026. The company said the financial results will be approved by its Board of Directors on May 19, 2026. HCG is slated to announce the Q4 and FY26 results on May 20, 2026. The update matters for investors because it combines a strong full-year operating picture with a sharp quarterly headline loss that the company attributes to unrealised items.

Full-year operating performance: volumes and revenue growth

HCG said sales volume increased 20% during the year, which supported revenue growth from ₹2,153 crore to ₹2,569 crore. Total income also rose to ₹2,660 crore from ₹2,279 crore. The company linked the improvement to higher volumes and better control on input costs. It also reported more than 90% capacity utilisation during the year, alongside operating margins that remained stable in the 15% to 20% range.

Profitability: EBITDA, margins, and profit movement

The company reported EBITDA rising from ₹388 crore to ₹497 crore, with EBITDA margin increasing from 17% to 19%. It also reported DBT increasing from ₹148 crore to ₹246 crore, which it described as a 66% growth. Net profit increased from ₹101 crore to ₹181 crore. In its commentary, HCG attributed the improvement to higher volumes and better input-cost control, alongside the broader operational performance during the year.

Balance sheet position: debt and treasury

HCG stated it remains financially strong with no long-term debt as of March 30, 2026. It also reported a treasury of around ₹792 crore. These disclosures are likely to be tracked closely around the results, especially as hospital operators balance growth investments with cost control and working capital management.

Quarterly headline: ₹189 crore loss and the stated reason

For the quarter, HCG reported a loss of ₹189 crore. The company said this was mainly attributable to an unrealised loss arising from fair impact on foreign investments, alongside rapid rupee depreciation, which it said led to a 5% move within the quarter. HCG added that these were entirely unrealised losses and that it has taken their impact in the books as per applicable Indian accounting standards. Excluding the unrealised losses, the company said its operating margin for the quarter remained intact and reasonably comparable with previous quarters.

Dividend recommendation for FY26

HCG said its Board of Directors has recommended a final dividend of ₹3.4 per equity share (face value ₹2), subject to shareholder approval at the upcoming annual general meeting. Dividend decisions are typically assessed alongside cash levels and capital needs, particularly when the company is also reporting capacity utilisation above 90% during the year.

Stock check: latest quoted price in the report

In the market update included with the company context, the scrip was down 0.08% and was trading at ₹578 on the BSE. The price move provides a near-term reference point ahead of the earnings release and board approval.

Operating footprint and service lines highlighted

HCG’s context note describes its comprehensive cancer centres as providing diagnosis and treatment under one roof. It also operates fertility centres under the ‘Milann’ brand. Separately, HCG was described as operating 22 cancer centres (India and Africa) and 7 fertility centres under ‘Milann’.

Recent disclosed trend points: H1FY26 snapshot (as stated)

In the H1FY26 operational snapshot provided, HCG reported revenue of ₹1,260.1 crore for H1FY26, up 16.8% year-on-year, and Q2FY26 revenue of ₹647.0 crore, up 17% year-on-year. Adjusted EBITDA for H1FY26 was reported at ₹235.2 crore, up 19.3% year-on-year, while Q2FY26 adjusted EBITDA was ₹123.3 crore, up 18% year-on-year. PAT for H1FY26 was reported at ₹21.0 crore, down 30% year-on-year, while Q2FY26 PAT was ₹16.3 crore versus ₹18.0 crore in Q2FY25. The same snapshot also mentioned established centres revenue of ₹1,109.1 crore and emerging centres revenue of ₹121.4 crore for H1FY26, with emerging centres’ EBITDA at ₹15.7 crore (up 118.1% year-on-year, as stated).

Key numbers table: FY26 annual metrics disclosed

Key numbers table: H1FY26 snapshot disclosed

Analysis: what investors will look for in the results

The upcoming audited results are likely to be read in two layers: the underlying operating trend and the accounting impact of unrealised items. On the operating side, HCG has disclosed higher volumes, revenue expansion, and improved EBITDA margins for the year, alongside capacity utilisation above 90%. On the reported quarterly outcome, the company has already pointed to fair-value movement on foreign investments and a 5% rupee depreciation during the quarter, framing the ₹189 crore loss as unrealised and accounting-standards driven. With a recommended final dividend and a stated nil long-term debt position as of March 30, 2026, investors are likely to focus on the audited financial statements for confirmation and granularity.

Conclusion: next date on the calendar

HCG’s Board is scheduled to approve the audited standalone and consolidated results on May 19, 2026, with the results announcement expected on May 20, 2026. Shareholders will also watch for updates related to the recommended final dividend, which remains subject to approval at the upcoming annual general meeting.